bradykinin Activators

Bradykinin Activators are a series of chemical compounds that serve to amplify the biological activity of bradykinin, a peptide known primarily for its roles in inflammation and blood pressure regulation. Compounds such as Captopril, Lisinopril, Enalapril, and Ramipril all function as ACE inhibitors, which prevent the degradation of bradykinin, thus sustaining and enhancing its vasodilatory effects. These inhibitors contribute to an elevated presence of bradykinin in the circulatory system, leading to more pronounced effects on lowering blood pressure. Additionally, compounds like Kallidin contribute to the pool of active bradykinin by serving as precursors that are converted into bradykinin, thereby amplifying its functional activity. The small molecule LM22A-4, which mimics bradykinin's action, and Rutoside, which may reduce the degradation of bradykinin, also contribute to the heightened activity of this peptide.

Furthermore, the paradoxical use of Icatibant, a bradykinin B2 receptor antagonist, can lead to the upregulation of bradykinin receptors, enhancing the sensitivity to bradykinin's effects. Diminazene and Amastatin both act as inhibitors of bradykinin degradation, promoting increased vasodilatory responses. Bradykinin activators are compounds that can increase the levels or activity of bradykinin, a peptide that plays a key role in various physiological processes. These activators work by different mechanisms, such as enhancing the production of bradykinin precursors, inhibiting the enzymes responsible for its degradation, or directly facilitating its release. Some activators can stimulate the expression of kallikreins, the enzymes that cleave kininogens to release bradykinin. Others can bind to and inhibit the activity of kininase enzymes like angiotensin-converting enzyme (ACE), which normally breaks down bradykinin into inactive peptides. By preventing the degradation of bradykinin, these activators ensure that bradykinin remains active in the system for an extended period.